ODI PHARMA Aktie

 

The Board of Directors of ODI Pharma AB (publ) (“ODI Pharma” or the “Company”) has resolved to propose a directed share issue of approximately SEK 2.0 million to strengthen the Company's financial position, enhance balance sheet flexibility and support the execution of ongoing operational activities. The proposal will be submitted for approval at an Extraordinary General Meeting scheduled to be held on 26 June 2025. Summary The Board of Directors of ODI Pharma has today resolved to propose that an Extraordinary General Meeting (EGM) approve a directed share issue of a total of 2,415,385...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 - March 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Third quarter (2025-01-01 – 2025-03-31) · The Group's net sales amounted to SEK 2,934,337 (13,856,539). · The Group's profit after financial items amounted to SEK -340,612 (1,389,713). · Result per share amounted to SEK -0.02 (0.09).* Nine months (2024-07-01 – 2025-03-31) · The Group's net sales amounted to...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2024 – December 2024. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Second quarter (2024-10-01 – 2024-12-31) · The Group's net sales amounted to SEK 0 (1,175). · The Group's profit after financial items amounted to SEK -2,562,520 (946,531). · Result per share amounted to SEK -0,16 (0.06).* Six months (2024-07-01 – 2024-12-31) · The Group's net sales amounted to SEK -4,965...

ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025. The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company's stock to facilitate trading. The agreement with Parteo has now been terminated and will expire on March 14, 2025. For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com...

Today, the 30[th] of December 2024, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority. For more detailed information on the content of the resolutions, please refer to the notice of the Annual General Meeting. Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to...

ODI Pharma AB's ("ODI" or the "Company") preferential issue of shares, with a subscription period ending on December 10, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is December 27, 2024, and the stop day is January 2, 2025. In November 2024, ODI carried out a rights issue which provided the Company with approximately SEK 2.2 million before transaction costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in...

The subscription period in ODI Pharma AB's ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on December 10, 2024. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs. Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a...

ODI Pharma AB ("ODI" or the "Company") provides an update on Poland's expanding medical cannabis market, which remains an important focus of the Company's strategy. Recent regulatory changes in Poland highlight ODI's established position in one of Europe's most promising markets for medical cannabis. With ODI Pharma's sales during the current calendar year, ODI Pharma reached it's previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024. ODI Pharma has...

Das Instrument 6OD SE0013409760 ODI PHARMA AB EQUITY wird ex Kapitalmassnahme gehandelt am 21.11.2024 The instrument 6OD SE0013409760 ODI PHARMA AB EQUITY is traded ex capital adjustment on 21.11.2024...

Das Instrument 6OD SE0013409760 ODI PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 20.11.2024 und ex Kapitalmassnahme am 21.11.2024 The instrument 6OD SE0013409760 ODI PHARMA AB EQUITY is traded cum capital adjustment on 20.11.2024 and ex capital adjustment on 21.11.2024...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of ODI Pharma AB ("ODI" or the "Company") has today, on October 30, 2024, resolved to carry out an issue of shares (the "...

Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on November 19, 2024. Malcolm Allan has extensive experience in senior positions within global companies and political campaigns. For the past three years, he has been serving as Vice President at Tilray Brands Inc. Prior to that, he was the Global COO for Havas Media and Managing Director for Prudential in London, UK. He holds a Bachelor of Arts with honors in Political Science and Economics from McGill University.   For more information about the...

The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19 November 2024 at 14.30 at the company's premises at Östermalmstorg 1, 114 42 in Stockholm. Eligibility and registration Shareholders who wish to participate in the General Meeting shall · be entered in the share register maintained by Euroclear Sweden AB on 11 November 2024, and · notify the company no later than on 13 November 2024 by e-mail to info@odipharma.com. The notification shall state full name, personal or corporate identity number,...

ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis provider in Switzerland. The delivery marks a symbolic milestone in ODI's market expansion efforts as it is the first delivery to the Swiss market. The delivery, which is facilitated through ODI's Swiss subsidiary, is less significant in terms of economic value but more important from a strategic point of view. Exploration of Other European Markets ODI Pharma is consolidating its position in the Eastern European medical cannabis market and is exploring...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Third quarter (2024-01-01 – 2024-03-31) The Group's net sales amounted to SEK 13,856,539 (10,801). The Group's profit after financial items amounted to SEK 1,389,713 (-942,440). Result per share amounted to SEK 0,09 (-0.06).*   Nine months (2023-07-01 – 2024-03-31) The Group's net sales amounted to SEK 14,777,194 (112,...